GlassScriptPhysician profile
Glynelle White
NPI 1841538543
$5,687.37
in general payments reported to CMS, 2019-2025
16 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,460 · 2022: $400 · 2023: $436 · 2024: $273 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,276.04 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $254.42 | 2021-2023 | |
| Corcept Therapeutics | $242.73 | 2021-2025 | Korlym |
| Medtronic, INC. | $218.35 | 2022-2024 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $160.76 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $142.52 | 2022-2023 | |
| Mannkind Corporation | $73.19 | 2021-2022 | |
| Abbott Laboratories | $71.12 | 2024-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $66.06 | 2021-2022 | |
| Amgen INC. | $59.38 | 2021-2022 | |
| Nevro Corp. | $38.97 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.81 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.50 | 2022 | |
| Tandem Diabetes Care, INC. | $17.60 | 2022 | |
| Sobi, INC | $15.97 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $12.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glynelle White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.